Fortress Biotech Reports Disappointing FY Earnings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Should l Buy FBIO?
Source: seekingalpha
- Disappointing Earnings Report: Fortress Biotech's FY GAAP EPS of -$0.07 missed expectations by $0.39, indicating a significant decline in profitability that could negatively impact investor confidence.
- Lackluster Revenue Growth: The company reported revenue of $63.26 million, a 9.7% year-over-year increase, yet it fell short of expectations by $10.08 million, reflecting unmet market demand that may affect future business development strategies.
- Deteriorating Cash Position: As of December 31, 2025, Fortress's cash and cash equivalents totaled $79.4 million, down $6.8 million from $86.2 million on September 30, 2025, indicating pressure on cash management that could limit future investment capabilities.
- Annual Cash Flow Improvement: Despite a decrease in cash flow for the fourth quarter, cash and cash equivalents increased by $22.1 million compared to December 31, 2024, suggesting an overall improvement in financial health for the year that may support future strategic investments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FBIO
Wall Street analysts forecast FBIO stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.700
Low
4.50
Averages
10.75
High
17.00
Current: 2.700
Low
4.50
Averages
10.75
High
17.00
About FBIO
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fortress Biotech Reports Disappointing FY Earnings
- Disappointing Earnings Report: Fortress Biotech's FY GAAP EPS of -$0.07 missed expectations by $0.39, indicating a significant decline in profitability that could negatively impact investor confidence.
- Lackluster Revenue Growth: The company reported revenue of $63.26 million, a 9.7% year-over-year increase, yet it fell short of expectations by $10.08 million, reflecting unmet market demand that may affect future business development strategies.
- Deteriorating Cash Position: As of December 31, 2025, Fortress's cash and cash equivalents totaled $79.4 million, down $6.8 million from $86.2 million on September 30, 2025, indicating pressure on cash management that could limit future investment capabilities.
- Annual Cash Flow Improvement: Despite a decrease in cash flow for the fourth quarter, cash and cash equivalents increased by $22.1 million compared to December 31, 2024, suggesting an overall improvement in financial health for the year that may support future strategic investments.
See More
Fortress Biotech Sells Priority Review Voucher for $205 Million
- Voucher Sale: Fortress Biotech's subsidiary Cyprium Therapeutics is selling its Rare Pediatric Disease Priority Review Voucher for $205 million, which is expected to significantly enhance the company's liquidity and support future R&D efforts.
- Proceeds Allocation: 20% of the sale proceeds will be allocated to the Eunice Kennedy Shriver National Institute of Child Health and Human Development, reflecting the company's commitment to social responsibility while potentially influencing future collaboration opportunities.
- FDA Approval and Market Reaction: The drug ZYCUBO received FDA approval in January for treating Menkes disease, and Fortress's stock surged 10% following the announcement, indicating increased market confidence in the company's product pipeline.
- Future Development Potential: Cyprium is also developing a gene therapy for Menkes disease to be used in conjunction with ZYCUBO, which, if successful, could further enhance the company's competitiveness in the rare disease sector and attract more investor interest.
See More
Cyprium Sells Rare Disease Priority Review Voucher for $205 Million
- Successful Asset Transaction: Cyprium Therapeutics entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to Sentynl Therapeutics for gross proceeds of $205 million, which is expected to significantly enhance the company's financial position and shareholder value.
- FDA Approval Milestone: ZYCUBO (copper histidinate) received FDA approval in January 2026, marking a significant advancement for Cyprium in treating Menkes disease and further solidifying its market position in rare diseases.
- Future Revenue Potential: Cyprium will continue to receive tiered royalties on net sales of ZYCUBO and has the potential to earn up to $129 million in development and sales milestones, demonstrating the long-term profitability and competitive edge of its product line.
- Strategic Development Direction: This transaction not only showcases Cyprium's ongoing execution in value-generating corporate transactions but also lays the groundwork for advancing its AAV-ATP7A gene therapy toward clinical development, expanding treatment options for Menkes disease in alignment with the company's long-term strategic goals.
See More
Cyprium Sells Rare Disease Priority Review Voucher for $205 Million
- Significant Transaction Value: Cyprium Therapeutics has entered into a definitive asset purchase agreement with Sentynl Therapeutics to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 million, which is expected to significantly enhance the company's cash flow and financial stability.
- FDA Approval Impact: The approval of ZYCUBO (copper histidinate) by the FDA on January 12, 2026, marks a critical milestone for Cyprium in treating Menkes disease, likely driving market demand and enhancing the company's reputation in the biopharmaceutical sector.
- Future Revenue Potential: Cyprium remains eligible to receive tiered royalties on net sales of ZYCUBO and up to $129 million in aggregate development and sales milestones, indicating strong potential for revenue growth in the future.
- Strategic Execution Success: The sale of the PRV aligns with Cyprium's recent FDA approvals, demonstrating the company's ongoing commitment to value-generating corporate transactions, which is expected to lay a solid foundation for future profitability.
See More
FORTRESS BIOTECH INC - CYPRIUM TO REMIT 20% OF PRV SALE REVENUE TO NIH INSTITUTE
Company Announcement: Fortress Biotech Inc. has announced that its subsidiary, Cyprium Therapeutics, will allocate 20% of the proceeds from its recent sale to the NHI Institute.
Financial Impact: This decision reflects the company's commitment to supporting research and development initiatives through the NHI Institute.
See More
Sanofi Secures EU Approval for Teizeild, Demonstrating Significant Efficacy in Type 1 Diabetes
- New Drug Approval: Sanofi's Teizeild receives EU approval as the first disease-modifying therapy for Stage 2 Type 1 Diabetes, demonstrating a median delay of 48.4 months to Stage 3 T1D, significantly enhancing patient quality of life and strengthening the company's competitive position in diabetes treatment.
- FDA Approval: Fortress Biotech's ZYCUBO gains FDA approval as the first treatment for Menkes Disease, showing nearly an 80% reduction in mortality risk when used early, laying a solid foundation for future market expansion and revenue growth.
- Acquisition Deal: Boston Scientific's $14.5 billion acquisition of Penumbra reflects its strategic expansion in interventional therapies, expected to enhance its leadership in vascular treatments and drive future revenue growth.
- Clinical Trial Progress: Creative Medical's CELZ-201 shows significant improvement in 79% of patients in the ADAPT trial for chronic lower back pain, indicating the therapy's clinical potential and likely attracting further investment and partnership opportunities.
See More
Fortress Biotech Reports Disappointing FY Earnings
- Disappointing Earnings Report: Fortress Biotech's FY GAAP EPS of -$0.07 missed expectations by $0.39, indicating a significant decline in profitability that could negatively impact investor confidence.
- Lackluster Revenue Growth: The company reported revenue of $63.26 million, a 9.7% year-over-year increase, yet it fell short of expectations by $10.08 million, reflecting unmet market demand that may affect future business development strategies.
- Deteriorating Cash Position: As of December 31, 2025, Fortress's cash and cash equivalents totaled $79.4 million, down $6.8 million from $86.2 million on September 30, 2025, indicating pressure on cash management that could limit future investment capabilities.
- Annual Cash Flow Improvement: Despite a decrease in cash flow for the fourth quarter, cash and cash equivalents increased by $22.1 million compared to December 31, 2024, suggesting an overall improvement in financial health for the year that may support future strategic investments.
See More
Fortress Biotech Sells Priority Review Voucher for $205 Million
- Voucher Sale: Fortress Biotech's subsidiary Cyprium Therapeutics is selling its Rare Pediatric Disease Priority Review Voucher for $205 million, which is expected to significantly enhance the company's liquidity and support future R&D efforts.
- Proceeds Allocation: 20% of the sale proceeds will be allocated to the Eunice Kennedy Shriver National Institute of Child Health and Human Development, reflecting the company's commitment to social responsibility while potentially influencing future collaboration opportunities.
- FDA Approval and Market Reaction: The drug ZYCUBO received FDA approval in January for treating Menkes disease, and Fortress's stock surged 10% following the announcement, indicating increased market confidence in the company's product pipeline.
- Future Development Potential: Cyprium is also developing a gene therapy for Menkes disease to be used in conjunction with ZYCUBO, which, if successful, could further enhance the company's competitiveness in the rare disease sector and attract more investor interest.
See More
Cyprium Sells Rare Disease Priority Review Voucher for $205 Million
- Successful Asset Transaction: Cyprium Therapeutics entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to Sentynl Therapeutics for gross proceeds of $205 million, which is expected to significantly enhance the company's financial position and shareholder value.
- FDA Approval Milestone: ZYCUBO (copper histidinate) received FDA approval in January 2026, marking a significant advancement for Cyprium in treating Menkes disease and further solidifying its market position in rare diseases.
- Future Revenue Potential: Cyprium will continue to receive tiered royalties on net sales of ZYCUBO and has the potential to earn up to $129 million in development and sales milestones, demonstrating the long-term profitability and competitive edge of its product line.
- Strategic Development Direction: This transaction not only showcases Cyprium's ongoing execution in value-generating corporate transactions but also lays the groundwork for advancing its AAV-ATP7A gene therapy toward clinical development, expanding treatment options for Menkes disease in alignment with the company's long-term strategic goals.
See More
Cyprium Sells Rare Disease Priority Review Voucher for $205 Million
- Significant Transaction Value: Cyprium Therapeutics has entered into a definitive asset purchase agreement with Sentynl Therapeutics to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 million, which is expected to significantly enhance the company's cash flow and financial stability.
- FDA Approval Impact: The approval of ZYCUBO (copper histidinate) by the FDA on January 12, 2026, marks a critical milestone for Cyprium in treating Menkes disease, likely driving market demand and enhancing the company's reputation in the biopharmaceutical sector.
- Future Revenue Potential: Cyprium remains eligible to receive tiered royalties on net sales of ZYCUBO and up to $129 million in aggregate development and sales milestones, indicating strong potential for revenue growth in the future.
- Strategic Execution Success: The sale of the PRV aligns with Cyprium's recent FDA approvals, demonstrating the company's ongoing commitment to value-generating corporate transactions, which is expected to lay a solid foundation for future profitability.
See More
FORTRESS BIOTECH INC - CYPRIUM TO REMIT 20% OF PRV SALE REVENUE TO NIH INSTITUTE
Company Announcement: Fortress Biotech Inc. has announced that its subsidiary, Cyprium Therapeutics, will allocate 20% of the proceeds from its recent sale to the NHI Institute.
Financial Impact: This decision reflects the company's commitment to supporting research and development initiatives through the NHI Institute.
See More
Sanofi Secures EU Approval for Teizeild, Demonstrating Significant Efficacy in Type 1 Diabetes
- New Drug Approval: Sanofi's Teizeild receives EU approval as the first disease-modifying therapy for Stage 2 Type 1 Diabetes, demonstrating a median delay of 48.4 months to Stage 3 T1D, significantly enhancing patient quality of life and strengthening the company's competitive position in diabetes treatment.
- FDA Approval: Fortress Biotech's ZYCUBO gains FDA approval as the first treatment for Menkes Disease, showing nearly an 80% reduction in mortality risk when used early, laying a solid foundation for future market expansion and revenue growth.
- Acquisition Deal: Boston Scientific's $14.5 billion acquisition of Penumbra reflects its strategic expansion in interventional therapies, expected to enhance its leadership in vascular treatments and drive future revenue growth.
- Clinical Trial Progress: Creative Medical's CELZ-201 shows significant improvement in 79% of patients in the ADAPT trial for chronic lower back pain, indicating the therapy's clinical potential and likely attracting further investment and partnership opportunities.
See More
